Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00073749 · ClinicalTrials.gov registry record · Phase 1
Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
A Phase 1 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 79
- Enrollment target
NCT00073749 is a Phase 1 study that has completed, run by Pfizer. The registered enrollment target is 79 participants.
The verdict
NCT00073749, a Phase 1 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 79 participants
- Enrollment target
Study Summary
To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
Interventions
- DRUG Inotuzumab ozogamicin [CMC-544]
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 79 participants |
| Start Date | 2003-08 |
| Est. Completion | 2010-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00073749
The ClinicalTrials.gov registry entry for NCT00073749 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 79 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inotuzumab ozogamicin [CMC-544] is the first listed.
NCT00073749 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00073749 about?
NCT00073749 is a clinical study titled "Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma". To determine the Maximum Tolerated Dose (MTD), the tolerability, and the initial safety profile of CMC-544 in subjects with B-cell Non-Hodgkin's Lymphoma (NHL).
What is the current status of trial NCT00073749?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 79 participants. The study started on 2003-08. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00073749?
The interventions under investigation include: Inotuzumab ozogamicin [CMC-544] (DRUG).
Who is sponsoring clinical trial NCT00073749?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.